Novel targets to cure primary myelofibrosis from studies on Gata1low mice

Maria Zingariello, Fabrizio Martelli, Paola Verachi, Claudio Bardelli, Francesca Gobbo, Maria Mazzarini, Anna Rita Migliaccio

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


In 2002, we discovered that mice carrying the hypomorphic Gata1low mutation that reduces expression of the transcription factor GATA1 in megakaryocytes (Gata1low mice) develop myelofibrosis, a phenotype that recapitulates the features of primary myelofibrosis (PMF), the most severe of the Philadelphia-negative myeloproliferative neoplasms (MPNs). At that time, this discovery had a great impact on the field because mutations driving the development of PMF had yet to be discovered. Later studies identified that PMF, as the others MPNs, is associated with mutations activating the thrombopoietin/JAK2 axis raising great hope that JAK inhibitors may be effective to treat the disease. Unfortunately, ruxolitinib, the JAK1/2 inhibitor approved by FDA and EMEA for PMF, ameliorates symptoms but does not improve the natural course of the disease, and the cure of PMF is still an unmet clinical need. Although GATA1 is not mutated in PMF, reduced GATA1 content in megakaryocytes as a consequence of ribosomal deficiency is a hallmark of myelofibrosis (both in humans and mouse models) and, in fact, a driving event in the disease. Conversely, mice carrying the hypomorphic Gata1low mutation express an activated TPO/JAK2 pathway and partially respond to JAK inhibitors in a fashion similar to PMF patients (reduction of spleen size but limited improvement of the natural history of the disease). These observations cross-validated Gata1low mice as a bona fide animal model for PMF and prompted the use of this model to identify abnormalities that might be targeted to cure the disease. We will summarize here data generated in Gata1low mice indicating that the TGF-β/P-selectin axis is abnormal in PMF and represents a novel target for its treatment.

Original languageEnglish
Pages (from-to)131-141
Number of pages11
JournalIUBMB Life
Issue number1
StatePublished - 1 Jan 2020
Externally publishedYes


  • Gata1
  • P-selectin
  • TGF-β
  • cancer supporting microenvironment
  • hematopoietic stem cells
  • megakaryocytes
  • primary myelofibrosis


Dive into the research topics of 'Novel targets to cure primary myelofibrosis from studies on Gata1low mice'. Together they form a unique fingerprint.

Cite this